open access

Vol 10, No 1 (2015)
Review Papers
Published online: 2015-03-02
Get Citation

Which hypertensive patient benefits the most from treatment with fixed-dose combination of losartan and amlodipine?

Beata Wożakowska-Kapłon, Paweł Salwa
DOI: 10.5603/FC.2015.0001
·
Folia Cardiologica 2015;10(1):38-44.

open access

Vol 10, No 1 (2015)
Review Papers
Published online: 2015-03-02

Abstract

Combination of antihypertensive agents can better control blood pressure and reduce the number and severity of drugs side effects than a monotherapy. Calcium channel blockers and angiotensin II receptor type-1 blockers are effective antihypertensive drugs. Losartan and amlodipine are frequently used as first-line therapy in hypertensive patients, and combining these two drug has also been shown to be effective and safe in lowering blood pressure. Early initiation of amlodipine/losartan combination followed by subsequent dose escalation in patients who have not achieved recommended blood pressure levels may be particularly beneficial for patients with hypertension and metabolic syndrome, diabetes, pulmonary diseases and hyperuricaemia.

Abstract

Combination of antihypertensive agents can better control blood pressure and reduce the number and severity of drugs side effects than a monotherapy. Calcium channel blockers and angiotensin II receptor type-1 blockers are effective antihypertensive drugs. Losartan and amlodipine are frequently used as first-line therapy in hypertensive patients, and combining these two drug has also been shown to be effective and safe in lowering blood pressure. Early initiation of amlodipine/losartan combination followed by subsequent dose escalation in patients who have not achieved recommended blood pressure levels may be particularly beneficial for patients with hypertension and metabolic syndrome, diabetes, pulmonary diseases and hyperuricaemia.

Full Text:

View HTML
Get Citation

Keywords

hypertension, fixed-dose combination, losartan, amlodipine

About this article
Title

Which hypertensive patient benefits the most from treatment with fixed-dose combination of losartan and amlodipine?

Journal

Folia Cardiologica

Issue

Vol 10, No 1 (2015)

Pages

38-44

Published online

2015-03-02

DOI

10.5603/FC.2015.0001

Bibliographic record

Folia Cardiologica 2015;10(1):38-44.

Keywords

hypertension
fixed-dose combination
losartan
amlodipine

Authors

Beata Wożakowska-Kapłon
Paweł Salwa

References (20)
  1. Mancia G, Fagard R, Narkiewicz K, et al. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku. Kardiologia Polska. 2013; 71(III): 27–118.
  2. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA. 2004; 292(19): 2350–2356.
  3. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension. 2005; 45(2): 198–202.
  4. Widecka K, Grodzick T, Narkiewicz K, et al. Zasady postępowania w nadciśnieniu tętniczym — 2011 roku. Wytyczne Polskiego Towarzystwa ienia iczego. Nadciśn Tętn. 2011; 15: 55–82.
  5. Mason RP, Marche P, Hintze TH. Novel vascular biology of third-generation L-type calcium channel antagonists: ancillary actions of amlodipine. Arterioscler Thromb Vasc Biol. 2003; 23(12): 2155–2163.
  6. Dahlöf B, Sever PS, Poulter NR, et al. ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366(9489): 895–906.
  7. Jamerson K, Weber MA, Bakris GL, et al. ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23): 2417–2428.
  8. Kim SH, Ryu KH, Lee NH, et al. Efficacy of fixed-dose amlodipine and losartan combination compared with amlodipine monotherapy in stage 2 hypertension: a randomized, double blind, multicenter study. BMC Res Notes. 2011; 4: 461.
  9. Kang SM, Youn JC, Chae SC, et al. Comparative efficacy and safety profile of amlodipine 5 mg/losartan 50 mg fixed-dose combination and amlodipine 10 mg monotherapy in hypertensive patients who respond poorly to amlodipine 5 mg monotherapy: an 8-week, multicenter, randomized, double-blind phase III noninferiority study. Clin Ther. 2011; 33(12): 1953–1963.
  10. Kohlmann O, Oigman W, Mion D, et al. [The "LOTHAR" study: evaluation of efficacy and tolerability of the fixed combination of amlodipine and losartan in the treatment of essential hypertension]. Arq Bras Cardiol. 2006; 86(1): 39–51.
  11. Unniachan S, Wu D, Rajagopalan S, et al. Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials. J Clin Hypertens (Greenwich). 2014; 16(9): 671–677.
  12. Lindholm LH, Ibsen H, Dahlöf B, et al. LIFE Study Group, LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311): 995–1003.
  13. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007; 369(9557): 201–207.
  14. Myou S, Fujimura M, Kamio Y, et al. Effect of losartan, a type 1 angiotensin II receptor antagonist, on bronchial hyperresponsiveness to methacholine in patients with bronchial asthma. Am J Respir Crit Care Med. 2000; 162(1): 40–44.
  15. Chan P, Tomlinson B, Huang TY, et al. Double-blind comparison of losartan, lisinopril, and metolazone in elderly hypertensive patients with previous angiotensin-converting enzyme inhibitor-induced cough. J Clin Pharmacol. 1997; 37(3): 253–257.
  16. Freedman DS, Williamson DF, Gunter EW, et al. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study. Am J Epidemiol. 1995; 141(7): 637–644.
  17. Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension. 2000; 36(6): 1072–1078.
  18. Viazzi F, Parodi D, Leoncini G, et al. Serum uric acid and target organ damage in primary hypertension. Hypertension. 2005; 45(5): 991–996.
  19. Dziubek K, Salwa P, Gorczyca-Michta I, et al. Znaczenie kliniczne hiperurykemii u hospitalizowanych chorych z nadciśnieniem tętniczym. Folia Cardiol. 2014; 9: 1–7.
  20. Liese AD, Mayer-Davis EJ, Haffner SM. Development of the multiple metabolic syndrome: an epidemiologic perspective. Epidemiol Rev. 1998; 20(2): 157–172.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl